Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 4/2015

01.04.2015 | Original Article - Cancer Research

Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer

verfasst von: Yan-Long Liu, Xu Gao, Yang Jiang, Gan Zhang, Zi-Cheng Sun, Bin-Bin Cui, Yan-Mei Yang

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Background and objectives

Enhancer of zeste 2 (EZH2), embryonic ectoderm development (EED), and suppressor of zeste 12 homolog (SUZ12), the key component of polycomb repressive complex 2, are of great importance in human cancer pathogenesis. This study was designed to investigate the clinical and prognostic significances of EZH2, EED and SUZ12 in colorectal cancer (CRC) patients.

Methods

The expression of EZH2, EED and SUZ12 mRNA was evaluated in 82 primary CRC and paired non-cancerous mucosa samples by qRT-PCR.

Results

We found that overall EZH2, EED and SUZ12 mRNA expression in the CRC tissues was significantly increased than in the non-cancerous tissue (p < 0.05). Increased EZH2, EED and SUZ12 mRNA expression was directly correlated with primary tumor size, regional lymph node metastases, distant metastasis and AJCC stage. Furthermore, CRC patients with higher level of EED, SUZ12 or EZH2 showed a worse disease-free survival (DFS) (p < 0.01). In multivariate analysis, the increased EZH2 expression may be a risk factor for the patients’ 3-year DFS (HR 2.517; 95 % CI 1.104, 5.736; p = 0.028). Furthermore, the k-means cluster analysis showed that high mRNA expression of EED, SUZ12 and EZH2 was significantly correlated with the aggressive clinical behavior and poor prognosis.

Conclusions

High expression of EED, SUZ12 and EZH2 might contribute to the CRC development/progression.
Literatur
Zurück zum Zitat Denisenko O, Shnyreva M, Suzuki H, Bomsztyk K (1998) Point mutations in the WD40 domain of Eed block its interaction with Ezh2. Mol Cell Biol 18:5634–5642PubMedCentralPubMed Denisenko O, Shnyreva M, Suzuki H, Bomsztyk K (1998) Point mutations in the WD40 domain of Eed block its interaction with Ezh2. Mol Cell Biol 18:5634–5642PubMedCentralPubMed
Zurück zum Zitat Hu S et al (2010) Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther 10:788–795CrossRefPubMed Hu S et al (2010) Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther 10:788–795CrossRefPubMed
Zurück zum Zitat Kim JH et al (2004) The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett 203:217–224CrossRefPubMed Kim JH et al (2004) The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett 203:217–224CrossRefPubMed
Zurück zum Zitat Wang CG, Ye YJ, Yuan J, Liu FF, Zhang H, Wang S (2010) EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis. World J Gastroenterol 16:2421–2427CrossRefPubMedCentralPubMed Wang CG, Ye YJ, Yuan J, Liu FF, Zhang H, Wang S (2010) EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis. World J Gastroenterol 16:2421–2427CrossRefPubMedCentralPubMed
Zurück zum Zitat Wolters T, Vissers KJ, Bangma CH, Schroder FH, van Leenders GJ (2010) The value of EZH2, p27(kip1), BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selecting men with significant prostate cancer at prostatectomy. BJU Int 106:280–286. doi:10.1111/j.1464-410X.2009.08998.x CrossRefPubMed Wolters T, Vissers KJ, Bangma CH, Schroder FH, van Leenders GJ (2010) The value of EZH2, p27(kip1), BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selecting men with significant prostate cancer at prostatectomy. BJU Int 106:280–286. doi:10.​1111/​j.​1464-410X.​2009.​08998.​x CrossRefPubMed
Metadaten
Titel
Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer
verfasst von
Yan-Long Liu
Xu Gao
Yang Jiang
Gan Zhang
Zi-Cheng Sun
Bin-Bin Cui
Yan-Mei Yang
Publikationsdatum
01.04.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 4/2015
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-014-1854-5

Weitere Artikel der Ausgabe 4/2015

Journal of Cancer Research and Clinical Oncology 4/2015 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.